天大药业中期报告2023

Stock Code: 00455 ()( Incorporated in the Cayman Islands with limited liability ) CONTENTS目錄 2Corporate Information3Management Discussion and Analysis6Disclosure of Interests and Other Information 10公司資料11管理層討論與分析14權益披露及其它資料 18Condensed Consolidated Statement of Profit or Lossand Other Comprehensive Income簡明綜合損益及其它全面收益表20Condensed Consolidated Statement of Financial Position簡明綜合財務狀況表22Condensed Consolidated Statement of Changes in Equity簡明綜合權益變動表23Condensed Consolidated Statement of Cash Flows簡明綜合現金流量表24Notes to the Condensed Consolidated Financial Information簡明綜合財務資料附註 CORPORATE INFORMATION NOMINATION COMMITTEE BOARD OF DIRECTORS Mr. Fang Wen Quan(Chairman)Mr. Lam Yat FaiMr. Chiu Sung Hong Executive Directors Mr. Fang Wen Quan(Chairman and Managing Director)Mr. Lui Man Sang RISK MANAGEMENT COMMITTEE Non-Executive Directors Mr. Chiu Sung Hong(Chairman)Mr. Fang Wen QuanMr. Lam Yat Fai Mr. Feng QuanmingMr. Zhong Tao (appointed on 29 August 2023)Mr. Shen Bo (resigned on 29 August 2023) PRINCIPAL BANKERS Independent Non-Executive Directors Agricultural Bank of ChinaBank of ChinaBank of CommunicationsChina Citic BankChina Merchants BankIndustrial and Commercial Bank of China Mr. Lam Yat FaiMr. Chiu Sung HongDr. Xian Yanfang (appointed on 27 June 2023)Mr. Chiu Fan Wa (resigned on 1 July 2023) AUDITOR REGISTERED OFFICE Ernst & YoungCertified Public AccountantsRegistered Public Interest Entity Auditor27/F, One Taikoo Place979 King’s RoadQuarry Bay, Hong Kong Cricket SquareHutchins DriveP. O. Box 2681Grand CaymanKY1-1111Cayman Islands HEAD OFFICE AND PRINCIPAL PLACE OFBUSINESS HONG KONG LEGAL ADVISER Woo, Kwan, Lee & Lo25th Floor, Jardine House1 Connaught Place, CentralHong Kong Suites 2405-2410, 24th FloorCITIC TowerNo. 1 Tim Mei AvenueCentralHong Kong COMPANY SECRETARY Mr. Lo Tai On HONG KONG SHARE REGISTRAR ANDTRANSFER OFFICE AUDIT COMMITTEE Tricor Secretaries Limited17th Floor, Far East Finance Centre16 Harcourt RoadHong Kong Mr. Lam Yat Fai(Chairman)Mr. Chiu Sung HongDr. Xian Yanfang (appointed on 27 June 2023)Mr. Zhong Tao (appointed on 29 August 2023)Mr. Chiu Fan Wa (resigned on 1 July 2023)Mr. Shen Bo (resigned on 29 August 2023) PLACE OF LISTING The Stock Exchange of Hong Kong Limited REMUNERATION COMMITTEE STOCK CODE00455 Mr. Chiu Sung Hong(Chairman)Mr. Fang Wen QuanMr. Lam Yat FaiDr. Xian Yanfang (appointed on 27 June 2023)Mr. Chiu Fan Wa (resigned on 1 July 2023) CORPORATE WEBSITE www.tiandapharma.com MANAGEMENT DISCUSSION A N D A N A L Y S I S CHANGE OF FINANCIAL YEAR END DATE In order to align the financial year end date of the Company with that of the principal operating subsidiaries of theCompany, the financial year end date of the Company has been changed from 31 March to 31 December in Novemberlast year. In view of this change, the interim consolidated financial statements cover the six-month period from 1 January2023 to 30 June 2023 (the “Current Interim Period”) and the comparative figures cover the six-month period from 1 April2022 to 30 September 2022 (the “Previous Interim Period”). BUSINESS REVIEW Starting from 2023, as the negative impacts of the pandemic has significantly receded, the Chinese economy issteadily recovering. Seizing this opportunity, the Group has consolidated its core products, expanded sales channels,advanced the development of the traditional Chinese medicine (“TCM”) businesses, and enriched product pipelines,continuously improving the operation and performance of its three business segments, namely the Pharmaceuticals andmedical technologies business, the Chinese medicine business, and the Medical and healthcare services. As a result, theGroup has achieved a total revenue of HK$303.5 million in the Current Interim Period, representing a 21.5% growthcompared with the Previous Interim Period. Excluding research and development (“R&D”) expenses, the Group hasturned its loss of HK$7.1 million in the Previous Interim Period into a profit of HK$3.78 million in the Current Interim Period. For the Pharmaceuticals and medical technologies business, the Group’s pediatric drug, Tuoen®Ibuprofen, has beenbenefited from the optimized epidemic prevention and control measures implemented by the Chinese government earlierthis year and the inclusion in the reference list of commonly used drugs for home treatment of COVID-19 patients(新冠病毒感染者居家治療常用藥參考表). As a result, the sales of Tuoen®Ibuprofen have grown by 89.5% in theCurrent Interim Period as compared with the Previous Interim Period, claiming the top three position in market share inMainland China. To meet the market demand for Tuoen®Ibuprofen and anticipated future growth, the Group adopted anunconventional approach and efficiently completed the construction of a new liquid-finished dosages production line andput it into operation within just three months. The Group’s cardio-cerebrovascular drug, Tuoping®Valsartan capsules, hasmaintained its position as the best-selling product in its catego